SPN003 / SPN004

Candidate drug screening is going to be completed.

SPN003/SPN004 are  innovative peptide drugs with synergistic effect on target,  with metabolic diseases including type 2 diabetes and obesity as the main indications.

SPN007

Candidate drug screening  has been completed, preclinical studies  are under way.

SPN007 is a new polypeptide drug with proprietary intellectual property rights. Its indications have expanded from simply lowering blood glucose levels in type 2 diabetes to treating obesity and non-alcoholic fatty liver disease (NASH).

SPN009

At the stage of preclinical studies.

Spn009 is an innovative long-acting hypoglycemic drug  for type 2 diabetes mellitus.

SPN-X

At the stage of candidate drug screening.

SPN-X is a peptide inhibitor against the novel coronavirus main protease.